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Abstract
Background: The diagnostic value of procalcitonin (PCT) for patients with autoimmune diseases (AID) remains
controversial and few studies focused on ICU patients. We sought to determine its diagnostic and prognostic
values in this clowd.
Methods: A prospective observational study was conducted in AID patients admitted to the ICU. Serum PCT levels
were measured on ICU admission and subsequently at days 1, 3, 5 and 7, and peak PCT levels within 24 h (PCTpeak)
were analyzed the utility for bacterial infection. The relationship of PCTpeak and SOFA score and severity of sepsis
was performed correlation analysis. The change of PCT over time reflected as PCT clearance was compared to ICU
28-day mortality.
Results: One hundred twelve patients were divided into bacterial infection group (group I, n = 54) and nonbacterial
condition group (group II, n = 58). The median PCTpeak (range, μg/L) was higher in the group I than that in the
group II (1.95 [0.38–37.56] vs. 0.64 [0.05–7.83], p = 0.002). PCTpeak had the best single predictor of bacterial infection
(area under the curve [AUC], 0.902, p < 0.001) with a sensitivity of 79.6 % and a specificity of 89.6 % at the threshold
of 0.94 μg/L. PCTpeak was also positive correlation with severity of sepsis (r = 0.731, p = 0.002), but its correlation
with SOFA score was only found in subjects with bacterial infection (r = 0.798, p < 0.001). Importantly, the 5-day PCT
clearance (PCTc-d5), rather than absolute PCT values, could earlier discriminate survivors (n = 73) from nonsurvivors
(n = 39) (68.8 ± 9.8 vs. 21.8 ± 17.5 %, p < 0.001, respectively). PCTc-d5 < 50 % was an independent predictor of
mortality (odds ratio 5.1, 95 % confidence interval 3.5 to 7.5; p = 0.001).
Conclusions: In critically ill patients with AID, elevated PCT levels are valuable for bacterial infection and are significantly
positive correlation with the septic severity. Five-day PCT clearance may provide independent prognostic information.
Larger, prospective trials are warranted to confirm the benefit.
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Background
Patients with autoimmune disease (AID) are more
susceptible to systemic bacterial infection with worse
outcome [1, 2]. Due to their compromised immune sta-
tuses, clinical, laboratory and molecular signs for infec-
tion are often subtle and nonspecific. Furthermore, it
has been shown that inflammatory signs can be masked
by immunosuppressants or corticosteroid and render
C-reactive protein (CRP) inconsistently reliable as a
biomarker for bacterial infection in this setting [3, 4].
So, there is an urgent need for a reliable biomarker
for the early diagnosis.
Over the last decade, Procalcitonin (PCT), a 116-
amino acid polypeptide and a precursor of calcitonin,
has become increasingly popular as a marker for bacter-
ial infection. It is well known that PCT is positively cor-
related with bacterial infection and severity of infection,
but also is not attenuated by steroids and has a more
helpful than CRP [5, 6]. Unfortunately, PCT has not
been extensively studied in patients with AID. The few
currently available studies provided conflicting results
[7–10]. Especially for critically ill patients, PCT is still
some debate because it may increase nonspecifically in a
variety of noninfectious conditions (e.g., systemic inflam-
mation, cardiogenic shock, organ dysfunction, and tissue
trauma) [5, 6]. Therefore, Little is known about the vari-
ation of initial PCT levels and its clearance in ICU pa-
tients with AID.
We described our preliminary experience in published
letter [11]. In this prospective observational study, we
sought to further define the potential role of PCT for
bacterial infection in this crowd. We measured PCT on
admission (day 0) and within 6 to 24 h after admission
(day 1), and the peak PCT concentration (PCTpeak) was
used to assess the diagnostic utility of bacterial infection.
In order to distinguish organ-dysfunction related induc-
tion and infection-related PCT response, we also studied
PCT concentrations in patients with or without bacterial
infection at a similar severity of organ dysfunction. Fur-
thermore, we performed PCT determinations every
other day through 1 week and hypothesised that early
change of PCT over time, or defined as PCT clearance,
is associated with ICU 28-day mortality.
Methods
Setting and participants
All AID patients (18 years or older) who were admitted to
medical ICU of our hospital between January 1, 2011 and
December 31, 2013 were consecutively screened. Patients
with small cell lung cancer, medullary thyroid carcinoma,
trauma or surgery which are served as the common non-
infectious causes of PCT elevations were excluded. In
addition, the following conditions will be excluded from
the final analysis for accurate classification: if they had
suspected infection but no pathogen could be identified; if
they had uncertain diagnosis as well as infection with dis-
ease flare at the same time; if they had incomplete data or
ICU length of stay (LOS) of less than 7 days.
This study was approved by the ethics committee of
Academy of Medical Sciences & Peking Union Medical
College Hospital (Approval Number: S-112) who waived
the need for informed consent in consideration of the
anonymous collection of data and observational nature
of the study.
Data collection
The following data were recorded upon ICU admission:
demographic characteristics, comorbidities, the type of
AID and the median time of diagnosis of AID, the me-
dian steroid dose and use of other immunosuppressants
in the 3 months before admission, the use of high-dose
steroid before ICU admission, prior hospitalization, rea-
sons for ICU admission, suspected of having a bacterial
infection and severity of organ dysfunction expressed by
the Sepsis-related Organ Failure Assessment (SOFA)
score [12]. During follow up, organ support (mechanical
ventilation, renal replacement therapy, and use of vaso-
pressors), finally confirmed infection, sources of infec-
tion, microbiological findings and septic condition (that
is, sepsis, severe sepsis or septic shock) according to
American College of Chest Physicians/Society of Critical
Care Medicine criteria [13], appropriate treatment of the
primary cause, ICU LOS and crude ICU 28 day-mortality
were also recorded.
Treatments and interventions
Patients were examined and treated according to the
practice of the institution. Empirical antimicrobial ther-
apy for suspected infection was administrated, which
was modified according to ongoing microbiological and
laboratory results. Routine cultures of blood, urine, and
of samples from trachea and suspected sites and sero-
logic test, or nucleic acid determination were taken for
diagnosis. The microbiological diagnostic workup in-
cluded a search for Legionella pneumophila, Chlamydia
pneumoniae, Mycoplasma pneumoniae, and respiratory
viruses (ie, herpes simplex virus, cytomegalovirus, re-
spiratory syncytial virus, and adenovirus) by polymerase
chain reaction, culture, or immunofluorescence. Appro-
priate stains and cultures for bacteria, mycobacteria,
fungi, and Pneumocystis jiroveci were performed. Chest
radiographs were performed in all cases, and CT scans
were obtained as indicated by the treating physicians.
Laboratory assay and PCT measurements
All assays were performed according to the manufac-
turers’ instructions and standard microbiology guidelines
[14]. Lower respiratory samples were obtained by
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tracheal aspiration, bronchoalveolar lavage or sputum
specimen. Only high-quality specimens (<10 epithelial
cells and > 25 white blood cells per low-power field)
were cultured, and more than 3+ of bacterial growths
using a semiquantitative culture method were consid-
ered positive.
PCT and laboratory tests (blood routine, liver and
kidney function test) were prospectively measured on
ICU admission (day 0) and subsequently at days 1, 3,
5 and 7. PCT measured using a commercially available
immunoluminometric assay system (Brahms Diagnostica,
Hennigsdorf bei Berlin, Germany) following the man-
ufacturer’s protocols. The lower detection limit is
0.05 μg/L.
Grouped and definition
The final determination of the patient’s diagnosis was
done retrospectively during a meeting of the ICU and
rheumatology physicians after patient discharge based
on results of microbiological cultures, radiographs
and serologic test.
The diagnosis categorized as either having a proven
bacterial infection (including co-infections of bacterial,
fungal and /or viral) or having a nonbacterial condition,
which was further divided into nonbacterial infection
(i.e., fungus or virus) and noninfectious conditions (i.e.,
disease flare or others). The bacterial infection was de-
fined as positive pathogen results from infection site or
blood, and with objective signs and symptoms and radio-
graphs according to International Sepsis Forum Consen-
sus Conference recommendations [15]. The diagnosis of
fungal infection was only included in the classification of
proven and probable based on the definitions of the
European Organization for the Research and Treatment
of Cancer-Mycoses Study Group (EORTC-MSG) [16].
The diagnosis of viral infection was established in a pa-
tient with positive serum samples or positive polymerase
chain reaction tests from cerebrospinal fluid or blood
[17]. The diagnosis of a disease flare was made when
there was a significant increase in the activity score
compared to the previous condition which was not
caused by any other conditions (such as infection or
drug). The disease activity index was calculated based on
the disease Activity Score or standard [18–24].
Statistical methods
All data are expressed as the mean (± SD) or median
(range) as appropriate. The χ2 test or Fisher’s exact
test was used to compare categorical variables. The
Student’s t-test or Mann–Whitney U test was used to
compare continuous variables. Univariate and multi-
variate analysis were used to identify factors associ-
ated with mortality. Variables yielding p values < 0.2
by univariate analysis, or those considered clinically
relevant despite p-values, were entered in the multi-
variate analysis. A p-value of < 0.05 was considered
statistically significant. Data were analyzed using SPSS
statistical software (version 17.0; SPSS Inc., Chicago,
IL, USA).
PCTpeak was considered for analyses of diagnosis ac-
curacy and expressed as the area under the receiver op-
erating characteristic curve (AUC). Among PCTpeak,
SOFA score and septic conditions, pearson's correlation
and the regression formula were calculated (y = a + bx).
PCT clearance (PCTc) was defined as percentage of delta
PCT (ΔPCT) concentration which is PCTpeak minus PCT
measured in the subsequent over PCTpeak. The formula is
as follows: PCTc-dx = (PCTpeak – PCTdX) / PCTpeak. The
values are negative with increasing concentrations and
positive with decreasing concentrations.
Results
Patients’ characteristics and grouping
One hundred twelve patients (44 males and 68 females)
selected among 150 AID patients were included. The
types of AID and the reasons for exclusion are listed in
Fig. 1. The patients’ age was 53.0 ± 17.1 years and me-
dian time of diagnosis of AID was 10.8 months (range,
2 weeks to 13 years). SOFA score on ICU admission was
6.9 ± 3.8 points. 99 patients need for mechanical ventila-
tion, 18 need for renal replacement therapy and 55 need
for vasopressor, respectively. ICU LOS and 28-day crude
ICU mortality were 12.5 (7 to 33) days and 34.8 % (39 of
112), respectively. The patients’ characteristics are sum-
marized in Table 1.
Of the 112 patients, 54 (48.2 %) had a bacterial in-
fection (group I) and 58 had a nonbacterial condi-
tion (group II). In the latter, nonbacterial infection
and noninfectious condition occurred in 29, respect-
ively. In the group I, the sourses of infection were as
follows: 15 bloodstream infection, 36 pulmonary and
3 central nervous system infection. The main organ-
isms were gram negative bacilli (43/54, 79.6 %) and
co-infection accounted for 27.8 % (15/54). In the
group of nonbacterial infection, the diagnosis was 4
candidemia, 23 nonbacterial pneumonia, one cyto-
megalovirus (CMV) encephalitis and one systemic
infection of EB virus (All etiological data are pre-
sented in Additional file 1). Moreover, the composi-
tions of noninfectious conditions were 26 cases of
disease flares and three cases of other noninfectious
complications (Fig. 1). In patients with disease activ-
ities, the manifestations are as follows: 14 active SLE
patients (SLEDAI score 13.8 ± 5.4 points); five of ac-
tive microscopic polyangiitis (BVAS 16.5 ± 5.6 points);
six cases with respiratory failure (including 2 of sys-
temic sclerosis, Wegener’s granulomatosis and derm-
atomyositis, respectively) due to connective tissue
Shi et al. BMC Anesthesiology  (2015) 15:137 Page 3 of 9
disease related interstitial lung disease and one with
scleroderma renal crisis.
PCT for initial diagnosis
Of all patients, the median PCTpeak (range) was 1.88
(0.05–37.56) μg/L and delayed PCTpeak occurred in
28 patients and were as follows: 10 of new onset
bacteremia, 9 of bacterial pneumonia, 6 of active
AID (SLE related diffuse alveolar hemorrhage, vascu-
litis related gastrointestinal bleeding and WG in two
cases, respectively), 2 of candidemia and one of SLE
with acute pulmonary edema. The median PCTpeak
(range, μg/L) was higher in the group I than that in
the group II (1.95 [0.38–37.56] vs. 0.64 [0.05–7.83],
p = 0.002), but similar in the subgroup of nonbacterial
infection and noinfectious condition (0.61 [0.08–7.83] vs.
0.67 [0.05–7.78], p = 0.917), respectively.
Based on clinical evaluations and PCT guide
(>0.5 μg/L), 92 cases and 67 cases were diagnosed as
suspected of having a bacterial infection on admis-
sion, respectively. PCTpeak had the better performance
for bacterial infection with an AUC of 0.902 (95 % CI
0.846–0.959; p < 0.001) as compared to temperature
(AUC = 0.472; 95 % CI 0.256–0.689; p = 0.783), leuco-
cytes (AUC = 0.606, 95 % CI 0.432–0.681; p = 0.286),
neutrophil percentage (AUC = 0.484, 95 % CI 0.291–
0.678; p = 0.876) and clinical comprehensive evalu-
ation (AUC = 0.651, 95 % CI 0.491–0.759; p = 0.166).
The cutoff point of 0.94 μg/L had a sensitivity of
79.6 %, specificity of 89.6 %, positive likelihood ratio
of 7.65, negative likelihood ratio of 0.22 and an
accuracy of 86.8 % for predicting bacterial infection
(Fig. 2).
PCT and severity of organ dysfunction and septic
condition
PCTpeak of all patients showed positive correlation with
severity of organ dysfunction expressed by the SOFA
score (r = 0.698, p < 0.001) (Table 2), but strongly posi-
tive correlation was only found in subjects with bacterial
infection (r = 0.798, p < 0.001), rather than in those with-
out (r = 0.205, p = 0.791). It was expressed with regres-
sion equation (y = a + bx) as follows: PCT = − 0.921 +
1.326 SOFA score and PCT = 0.153 + 0.038 SOFA score,
respectively. In other words that PCTpeak was still higher
in patients with bacterial infection than those without at
comparable levels of organ dysfunction (Table 3).
Othermore, analyzing of PCTpeak of 83 patients with
sepsis (18 of sepsis, 24 of severe sepsis an 41 of septic
shock) demonstrated that PCTpeak levels were also
positive correlation with the severity of sepsis (r = 0.731,
p = 0.002) and higher PCTpeak may progress to severe
sepsis or septic shock (Table 2).
PCT clearance (PCTc) and prognosis
PCT concentrations (μg/L) were similar between sur-
vivors and nonsurvivors (include both infectious and
non-infectious patients) throughout the 3-day period
(PCTpeak: 1.92 [0.10–37.56] vs. 1.83 [0.10–31.33], p = 0.79;
PCTd3: 1.35 [0.08–57.20] vs. 1.43 [0.08–25.92], p = 0.67,
survivors vs. nonsurvivors, respectively). Despite PCTd5
had a decline tendency in survivors than in nonsurvivors
Fig. 1 Study design showing patient allocation and diagnosis. SLE: systemic lupus erythematosus; DM: dermatomyositis; pSS: primary Sjogren’s syndrome;
RA: rheumatoid arthritis; SSc: systemic sclerosis; MCTD: mixed connective tissue diseas; AOSD: adult-onset Still’s disease; WG: Wegener’s granulomatosis; BSI:
bloodstream infection; CNS: central nervous system; CRF: chronic renal failule; ARF: acute renal failure; DAH: diffuse alveolar hemorrhage; GIB: gastrointestinal
bleeding; SRC: Sclerode rmarenal crisis; ILD: interstitial lung disease
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Table 1 Patients’ characteristics and outcome
Bacterial infection Nonbacterial condition Survivors Non-survivors
n = 54 n = 58 n = 73 n = 39
Demographic characteristics
Age, mean ± SD, yr. 52.5 ± 13.1 51.8 ± 15.8 53.1 ± 11.7 52.3 ± 17.6
Female, n (%) 33 (61.1 %) 38 (65.5 %) 47 (64.4 %) 24 (61.5 %)
Type of AID, n (%)
SLE 30 (55.6 %) 29 (50 %) 44 (60.3 %) 15 (38.5 %)b
Systemic vasculitis 5 (9.3 %) 7 (12.1 %) 7 (9.6 %) 5 (12.8 %)
Dermatomyositis 3 (5.6 %) 10 (17.2 %)a 4 (5.5 %) 9 (23.1 %)a
pSS 4 (7.4 %) 4 (6.9 %) 6 (8.2 %) 2 (5.1 %)
RA 3 (5.6 %) 2 (3.4 %) 3 (4.1 %) 2 (5.1 %)
SSc 3 (5.6 %) 2 (3.4 %) 3 (4.1 %) 2 (5.1 %)
MCTD 3 (5.6 %) 2 (3.4 %) 3 (4.1 %) 2 (5.1 %)
Others 3 (5.6 %) 2 (3.4 %) 3 (4.1 %) 2 (5.1 %)
Comorbid conditions, n (%)
Heart function grade > 3 (NYHA) 4 (7,4 %) 6 (10.3 %) 3 (4.1 %) 7 (17.9 %)a
Chronic renal insufficiency (CKD stage > 3) 5 (9.3 %) 6 (10.3 %) 4 (5.5 %) 7 (17.9 %)a
Prior hospitalization, days, median (range) 3.3 (1–38) 3.0 (1–33) 3.2 (1–35) 2.9 (1–38)
The treatment before ICU admission
The median equivalent prednisone dose, mg/d 43.2 ± 22.4 41.4 ± 25.2 40.2 ± 25.7 44.4 ± 21.5
Immunosuppressants, n (%) 11 (20.4 %) 13 (22.4 %) 18 (24.7 %) 6 (15.4 %)b
High dose steroid, n (%) 6 (19.4 %) 9 (31.0 %)b 5 (6.8 %) 10 (25.6 %)a
Antibiotic therapy, n (%) 44 (81.4 %) 50 (86.2 %) 61 (83.6 %) 33 (84.6 %)
Reasons for ICU admission, n (%)
Acute respiratory failure 24 (44.4 %) 24 (41.4 %) 26 (35.6 %) 22 (56.4 %)b
Acute kidney failure 1 (1.9 %) 5 (8.6 %)a 5 (6.8 %) 1 (2.6 %)
Conscious disturbance 3 (5.6 %) 8 (13.8 %)a 4 (5.5 %) 7 (17.9 %)a
Hypopressure of any reasons 10 (14.8 %) 8 (13.8 %) 14 (19.2 %) 4 (10.3 %)b
The coexistence of hypotension and respiratory failure 16 (29.6 %) 13 (22.4 %) 16 (21.9 %) 13 (33.3 %)b
Characteristics on admission
Body temperature, °C 38.2 ± 0.5 38.3 ± 0.7 38.3 ± 0.6 38.3 ± 0.3
Leucocytes, cells/mm3 10,300 ± 7200 10,100 ± 5600 10,100 ± 6400 10,200 ± 7600
Granulocyte, % 88.5 ± 18.9 88.1 ± 21.5 88.2 ± 15.1 87.9 ± 13.6
Neutropenia, n (%) 4 (7.4 %) 4 (6.9 %) 5 (6.8 %) 3 (7.7 %)
Serum creatinine, μmol/l 106.7 ± 28.1 108.2 ± 35.5 102.5 ± 35.5 110.5 ± 23.7
SOFA score, points 6.8 ± 3.1 6.2 ± 3.5 5.4 ± 2.2 8.9 ± 2.1a
Organ support, n (%)
mechanical ventilation 48 (88.9 %) 51 (87.9 %) 60 (82.2 %) 39 (100 %)b
renal replacement therapy 8 (14.8 %) 10 (17.2 %) 7 (11.0 %) 11 (28.2 %)a
vasopressor 26 (48.1 %) 29 (50.0 %) 30 (41.1 %) 25 (64.1 %)a
ICU new acquired severe sepsis, n (%) 18 (33.3 %) 23 (39.7 %) 21 (28.8 %) 20 (51,3 %)a
Duration of shock, days, median (range) 6.5 (3–15) 6.9 (2–14) 3.8 (2–10) 7.5 (7–15)a
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(1.03 [0.08–38.38] vs. 1.47 [0.08–37.73], respectively,
p = 0.06), PCTd7 was found significantly lower (0.53
[0.08–17.1] vs. 2.15 [0.08–110.10], respectively, p = 0.005).
By comprasion, 5-day PCT clearance (PCTc-d5) earliest
showed significant difference between 2 groups (68.8 ± 9.8
vs. 21.8 ± 17.5 %, p < 0.001, survivors vs. nonsurvivors, re-
spectively). On the contrary, the trendency of leukocytosis,
temperature and granulocyte percentage did not differ be-
tween 2 groups (p > 0.05 all). In particular, PCTc-d5 was
significantly faster in the survivors of bacterial infection
compared with those without (80.8 ± 15.7 vs. 35.8 ± 14.5 %,
respectively, p < 0.001).
PCT levels at days 1, 3, 5 and 7, PCT clearance and
other 17 prognostic variables with a p-value of <0.2 by
univariate analysis (Table 1) were included in the multi-
variable logistic regression analysis and demonstrated
five independent predictors of 28-day mortality. These
included PCTc-d5 < 50 % (odds ratio [OR] 5.1, 95 % con-
fidence interval [CI] 3.5 to 7.5, P = 0.01), SOFA > 8.9
score (OR 2.5, 95 % CI 1.4 to 3.6, P = 0.02), duration of
shock > 7 days (OR 3.6, 95 % CI 1.6 to 7.8, p = 0.02), in-
appropriate therapy of the primary cause (OR = 2.0, 95 %
CI 1.1 to 7.6, p = 0.03) and ICU new acquired severe
sepsis (OR 5.8, 95 % CI 3.2 to 8.7, p = 0.01).
Discussion
Early predicting severe infection remains a major issue
in management of AID patients. Our results suggested
that PCT is an accurate marker for the diagnosis of bac-
terial infections and its peak levels is related to the se-
verity of sepsis. Moreover,delayed PCT clearance may to
be a powerful predictor of mortality.
In contrast to previous data, demonstrating no diag-
nostic value for bacterial infection in AID patients [7, 8],
but in line with other reports [9, 10], we detected the
utility of PCT for differentiating between bacterial infec-
tion and nonbacterial condition. The ambiguous conclu-
sions may be attributable to several factors: First,
enrolled difference kind of AID or heterogeneous groups
of patients as controls. For example, some studies in-
cluded in the healthy individuals [9, 10], and others used
the full spectrum of AID, or certain AID or disease flares
[7, 8, 25, 26] and elevated PCT were found in patients
who have certain AID but no evidence of bacterial infec-
tion (such as adult-onset Still’s disease [25], Wegener’s
[27]). Sencond, the timing of the first PCT measurement
varied accounted for by the difficulty in determining the
time of onset of sepsis and the time of patient recruit-
ment. In the present study, the peak levels of PCT used
Table 1 Patients’ characteristics and outcome (Continued)
ICU stay, days, median (range) 13.1 (8–31) 13.6 (7–33) 12.5 (8–29) 13.9 (7–33)
Appropriate treatment of the primary cause, n (%) 28 (51.8 %) 26 (44.8 %) 42 (57.5 %) 12 (30.8 %)a
28-day ICU mortality, n (%) 18 (33.3 %) 21 (36.2 %) - -
AID autoimmune diseases; SLE systemic lupus erythematosus; pSS primary Sjogren’s syndrome
RA rheumatoid arthritis; SSc systemic sclerosis; MCTD mixed connective tissue disease
aP < 0.05 versus the control group; bP < 0.20 versus the control group
Fig. 2 Receiver operating curve (ROC) analysis on discrimination of bacterial infection. Peak PCT levels within 24 h (PCTpeak) had the better performance
for bacterial infection with an AUC of 0.902 and had a sensitivity of 79.6 %, specificity of 89.6 % at the threshold of 0.94 μg/L
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may provide better performance based on the potential
to detect a late increase of PCT, which is usually seen in
the early stages of infections, pretreatment or subacute
infections and was also demonstrated by our previous
investigation [28]. Third, the definition of infection is a
methodological limitation in all similar studies, com-
pared with those using only clinical criteria [7–11], in-
fection was defined microbiologic confirmed may be
further improved the diagnostic ability in our setting. All
of these may also be responsible for the varied cutoff
points of PCT for bacterial infection.
Forthermore, we also report different features of either
infection-related PCT response or organ-dysfunction re-
lated induction. Also in patients with organ-dysfunction,
there may be PCT induction, but this is usually not as
high as in bacterial infection at comparable levels of
organ dysfunction. This finding indicates that bacterial
infection still remains the primarily cause for PCT eleva-
tion in critically ill patients. In addition, a significantly
positive correlation between severity of sepsis and PCT
level will help in high-risk classification.
It is also important to identify markers that provide
prognostic information. In the present study, PCT clear-
ance was more useful than absolute level. Similar findings
were confirmed by other studies [29–31], however, our
study supplemented the work by extended to all patients,
not only in septic patients. It is very interesting to note
that various conditions other than bacterial infection may
induce PCT elevation, for example, severe trauma, pro-
longed cardiogenic shock, organ dysfunction, which
indicate the cytokine-like behavior of PCT during in-
flammation and infection [32]. As a result, the course
of PCT levels over time is a sign of alarm indicating a
high risk of organ dysfunction due to systemic inflamma-
tion. Therefore, we have reason to believe that failure to
decline in the PCT levels, regardless of the induced cause
(infection or organ-dysfunction), has been related to higher
mortality rates. That is why PCT clearance may influence
the prognosis of non-infectious. Published studies in acute
cardiac patients or surgery, acute ischemic stroke have
come to similar conclusions [33–35].
Several limitations of our study should also be noted.
First, we have included a heterogeneous population of
AID patients and different cutoff point may be needed
in different AID. While this diversity is routine in the
ICU. Second, the definition of infection is a methodo-
logical limitation and lead to misclassified or bias. Simi-
larly, the fact of antibiotic pretreatment before ICU
admission may also influence the identification of the
pathogen and misclassify, but we minimized the devi-
ation by using a retrospective diagnosis and excluding
the patients who had uncertain diagnosis or no path-
ogens were identified. Third, a single center study
may limit the general application of the results. Fur-
ther studies are needed to clarify the reliability of
PCT kinetics for outcome. Yet, our study is the first
to describe a PCT-c as independent determinant of
mortality and may play an important role in AID pa-
tients management.
Conclusion
PCT might be as a promising tool for early detection of
bacterial infection and risk stratification in critically ill
patients with AID. Dynamic change of PCT is associated
with prognosis. Additional studies are required to esti-
mate the reliability of threshold and PCT kinetics when
used patients management.
Table 2 Peak procalcitonin levels (PCTpeak) at different groups
of SOFA score and septic condition
SOFA PCTpeak, μg/L
Category of SOFA
1–6 (n = 78) 3.5 (2–6) 0.68 (0.05–5.88)
7–12 (n = 27) 9.3 (7–11) 3.85 (0.08–9.95)
13–18 (n = 5) 14.2 (13–15) 10.58 (4.77–29.90)
19–24 (n = 2) 19 (19) 28.74 (19.98–37.56)
Category according to septic condition
SIRS (n = 29) 3.3 (2–13) 0.67 (0.05–7.83)
Sepsis (n = 18) 4.1 (3–6) 1.73 (0.05–4.60)*
Severe sepsis (n = 24) 6.1 (4–7)** 4.81 (0.08–22.15)**
Septic shock (n = 41) 9.8 (6–20)*** 15.50 (0.08–37.56)***
Data presented as median values (range). SIRS, systemic inflammatory
response syndrome
*P < 0.05 versus SIRS, **P < 0.05 versus sepsis, ***P < 0.05 versus severe sepsis
Table 3 Procalcitonin (PCT) levels at various severities of organ dysfunction comparing patients with and without bacterial infection
Category of SOFA score (group I/group II) PCTpeak P value
Bacterial infection (group I) Nonbacterial condition (group II)
SOFA 1–6 (n = 32/46) 0.68 (0.59–5.88) 0.14 (0.05–0.33) 0.038
7–12 (n = 17/10) 7.8 (3.52–9.95) 0.25 (0.08–3.85) <0.001
13–18 (n = 3/2) 15.5 (13.83–29.90) 6.30 (4.77–7.83) 0.001
19–24 (n = 2/0) 28.7 (19.98–37.56) - -
Data presented as median values (range)
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Additional file
Additional file 1: Additional etiological findings in the patients with
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